Hao Xie, MD, PhD
Affiliations: | Oncology | Mayo Clinic at Rochester | |
| 2004-2009 | Chemistry | Princeton University, Princeton, NJ | |
| 2009-2014 | Medicine | Cleveland Clinic Lerner College of Medicine, Cleveland, OH, United States |
Google:
"Hao Xie"Mean distance: 8.23 | S | N | B | C | P |
Collaborators
Sign in to add collaborator| Yu Yuan | collaborator | 2021- | |
| Jianfeng Cai | collaborator | 2022- | |
| Glenn Martin Sammis | collaborator | 2004-2006 |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu J, Xie H. (2023) BRAF Non-V600 Mutations in Metastatic Colorectal Cancer. Cancers. 15 |
| Alem D, Yang X, Beato F, et al. (2023) Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer. Molecular Carcinogenesis |
| Liu J, Wang X, Sahin IH, et al. (2023) Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology |
| Bian Y, Alem D, Beato F, et al. (2022) Development of SOS1 Inhibitor-Based Degraders to Target -Mutant Colorectal Cancer. Journal of Medicinal Chemistry |
| Xie H, Liu J, Alem Glison DM, et al. (2021) The clinical advances of proteolysis targeting chimeras in oncology. Exploration of Targeted Anti-Tumor Therapy. 2: 511-521 |
| Xie H, Liu J, Yin J, et al. (2020) Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. The Oncologist |
| Xie H, Liu J, Ogden JR, et al. (2020) Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology |
| Xie H, Liu J, Yadav S, et al. (2019) The role of perioperative systemic therapy in localized pancreatic neuroendocrine neoplasms. Neuroendocrinology |
| Xie H, Yadav S, Keutgen X, et al. (2019) The role of perioperative systemic therapy in localized pancreatic neuroendocrine tumor. Journal of Clinical Oncology. 37: 322-322 |
| Xie H, Hogenson TL, Horn IP, et al. (2019) Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients. Journal of Clinical Oncology. 37: 3101-3101 |